Indaptus Therapeutics (NASDAQ:INDP) Releases Earnings Results

Indaptus Therapeutics (NASDAQ:INDP) issued its earnings results on Wednesday. The company reported ($2.98) EPS for the quarter, beating analysts’ consensus estimates of ($4.17) by $1.19, FiscalAI reports.

Indaptus Therapeutics Stock Performance

Shares of NASDAQ INDP traded down $0.45 during mid-day trading on Friday, reaching $2.51. The company had a trading volume of 39,274 shares, compared to its average volume of 226,154. The company has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.07 and a beta of 1.00. The stock has a fifty day moving average of $3.19 and a two-hundred day moving average of $7.54. Indaptus Therapeutics has a 12-month low of $2.22 and a 12-month high of $47.60.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on INDP. Wall Street Zen raised Indaptus Therapeutics to a “sell” rating in a report on Saturday, October 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.